22
Participants
Start Date
May 7, 2019
Primary Completion Date
July 25, 2019
Study Completion Date
July 25, 2019
Dolutegravir dispersible tablet
DTG will be available as an oral tablet with dosing strength of 5 mg 2 tablet will be dispersed in water will be administered orally for prescribed regimen.
Dolutegravir oral suspension
DTG will be available as an oral suspension with dosing strength of 5 mg per milliliter (ml) or 2 mg per ml with miglyol 812N or ethyl cellulose in miglyol 812N as vehicle for suspension administered orally for prescribed regimen.
Dolutegravir oral solution
DTG will be available as an oral solution with dosing strength of 2 mg per ml will be administered orally for prescribed regimen.
GSK Investigational Site, Nottingham
Lead Sponsor
ViiV Healthcare
INDUSTRY